Bispyridinium dienes:: Histone deacetylase inhibitors with selective activities

被引:42
|
作者
Perez-Balado, Carlos
Nebbioso, Angela
Rodriguez-Grana, Paula
Minichiello, Annunziata
Miceli, Marco
Altucci, Lucia
de Lera, Angel R.
机构
[1] Univ Vigo, Dept Quim Organ, Vigo 36310, Spain
[2] Univ Naples 2, Dipartimento Patol Gen, I-80138 Naples, Italy
[3] NOGEC, Naples Oncogenom Ctr, CEINGE Biotecnol Avanzata, Naples, Italy
关键词
D O I
10.1021/jm070028m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel synthetic route to the cyclostellettamines 1 using as the key step a microwave-mediated macrocyclic ring-closing metathesis of precursors bispyridinium dienes 10 followed by catalytic hydrogenation has been developed. The open-chain bispyridinium dienes 10 showed uniformly higher histone deacetylase (HDAC) inhibitory potency than the natural products. Diene 10b inhibited HDAC1 and was inactive on HDAC4, whereas 10a showed a weak inhibition of HDAC1 and a higher activity on HDAC4. Neither 10b nor 10a inhibited isoforms HDAC2 and HDAC3. Cell cycle analysis, cell differentiation, and apoptosis as well as evaluation of the acetylation status of H3 lysine tails, up-regulation of p21(WAF1/CIP1), and R-tubulin acetylation induced by the dienes 10 and cyclostellettamines 1 were also carried out on the human leukemia U937 cell line. These enzymatic and functional assays suggest that 10b is a HDAC1-selective inhibitor and 10a is a HDAC subclass IIa-selective inhibitor.
引用
收藏
页码:2497 / 2505
页数:9
相关论文
共 50 条
  • [31] Bioluminescent cell models for the detection of selective histone deacetylase inhibitors
    Linares, A.
    Boulahtouf, A.
    Boulle, N.
    Busson, M.
    Balaguer, P.
    Cavailles, V
    BULLETIN DU CANCER, 2008, 95 : S18 - S18
  • [32] Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors
    Varghese, Sheeba
    Senanayake, Thulani
    Murray-Stewart, Tracey
    Doering, Kim
    Fraser, Alison
    Casero, Robert A., Jr.
    Woster, Patrick M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (08) : 2447 - 2456
  • [33] A novel series of potent and selective histone deacetylase inhibitors.
    Jones, Philip
    Altamura, Sergio
    Chakravarty, Prasun K.
    Ingenito, Raffaele
    Petrocchi, Alessia
    Rowley, Michael
    Scarpelli, Rita
    Serafini, Sergio
    Steinkuhler, Christian
    CANCER RESEARCH, 2006, 66 (08)
  • [34] Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore
    Melesina, Jelena
    Praetorius, Lucas
    Simoben, Conrad V.
    Robaa, Dina
    Sippl, Wolfgang
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (13) : 1537 - 1540
  • [35] Selective Inhibitors of Histone Deacetylase 10 (HDAC-10)
    Pojani, Eftiola
    Barlocco, Daniela
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (11) : 2306 - 2321
  • [36] Explorative Study on Isoform-Selective Histone Deacetylase Inhibitors
    Suzuki, Takayoshi
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2009, 57 (09) : 897 - 906
  • [37] Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
    Kalin, Jay H.
    Bergman, Joel A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (16) : 6297 - 6313
  • [38] Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas
    Zhang, Yingjun
    Wong, C. H.
    Loong, Herbert H. F.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) : 868 - 869
  • [39] An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
    West, Alison C.
    Mattarollo, Stephen R.
    Shortt, Jake
    Cluse, Leonie A.
    Christiansen, Ailsa J.
    Smyth, Mark J.
    Johnstone, Ricky W.
    CANCER RESEARCH, 2013, 73 (24) : 7265 - 7276
  • [40] Potent histone deacetylase inhibitors:: N-hydroxybenzamides with antitumor activities
    Maeda, T
    Nagaoka, Y
    Kuwajima, H
    Seno, C
    Maruyama, S
    Kurotaki, M
    Uesato, S
    BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (16) : 4351 - 4360